Skip to main content

Table 4 Changes in CRP and ESR with treatment

From: Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

Time

Change in CRP (n = 37)

Change in ESR (n = 20)

 

oMTX

rMTX

oMTX

rMTX

3 months

-1.5 (-28.0 and +24.2)

-7.0 (-49.0 and +52.2)

-7.0 (-32.7 and +24.5)

-25.6 (-33.0 and +23.1)

6 months

-13.9 (-59.6 and +16.2)

-11.5 (-49.4 and +22.2)

-20.6 (-50.9 and +19.9)

-12.1 (-38.2 and +52.5)

9 months

-20.9 (-60.1 and +19.0)

-14.8 (-50.4 and +38.4)

-15.3 (-50.6 and +22.2)

-24.2 (-55.3 and +37.6)

12 months

-23.6 (-51.6 and +6.8)

-26.8 (-68.8 and +0.0)

-20.2 (-51.0 and +41.1)

-36.1 (-61.5 and +16.1)

AUC

-14.0 (-41.2 and +16.8)*

-10.3 (-53.0 and +37.9)*

-6.1 (-27.6 and +20.4)**

-17.7 (-45.9 and +25.1)**

  1. Shown are the relative improvements in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at 3, 6, 9, and 12 months after treatment initiation. Values are expressed as median (1st and 3rd quartile) of % change. *P = 0.80, by Wilcoxon test; **P = 0.43, by Wilcoxon test. oMTX, original methotrexate course; rMTX, re-employed methotrexate course.